Laxmi Dental Limited (LAXMIDENTL) Q1 2027 Earnings Call Transcript

Ladies and Chairman, good day, and welcome to the Lakshmi Dental Limited Q1FY27 Earnings Conference Call. As a reminder, all participant lines will remain in the listen-only mode, and there will be an opportunity for you to ask questions after the management's opening remarks. Should you need assistance during this conference call, please signal the operator by pressing star, then zero on your touchtone telephone. Please note that this conference is being recorded. Before we begin, a brief disclaimer. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantee of future performance of the company, and it may involve risk and uncertainties that are difficult to predict. I will now hand the conference over to Mr. Samir Merchant, Managing Director and CEO. Thank you, and over to you, sir.

Thank you. Good morning, everyone. A warm welcome to all of you, and thank you for joining our earnings call. On this call, we are joined by our CFO, Mr. Dharmesh Gattani, and Strategic Growth Advisors, our Investor Relations Advisors. The results and the presentation are uploaded on the Stock Exchange and Company website. I hope everybody has had a chance to look at them. I am pleased to share that Q1 F527 was a strong quarter for us, with broad-based growth across our dental laboratory and aligner solutions, providing a healthy start to the year. Our revenue for Q1 F527 stood at approximately 75 crore, registering a YOY growth of 13.9%. This was our highest ever quarterly revenue. During the quarter, we witnessed a healthy improvement in profitability, largely driven by a favorable product mix. EBITDA grew by 20.6% YOY, with margins improving to 19.2%, while PAT increased by 23.8% YOY, with margins standing at 13.8%. Coming to our segmental performance, our dental lab business delivered another strong quarter with revenue growing at 23.5% YOY, driven by healthy performance across both domestic and international market. Notably, the international business registered an impressive growth of 37.4% year-on-year. This momentum reflects the strong relationship and market presence we have built across global markets over the years. We are also looking forward to participating in the International Dental Show towards the end of the fiscal year. The IDS, known as the International Dental Show, is one of the world's premier dental exhibitions which happens every two years. which provides an excellent platform to showcase our products to dental laboratories, companies, and distributors from across the globe. It is also a great learning platform where we get to explore new technologies and innovative products that can be added to our portfolio. It is one of the few activities that helps us build better networks in the international markets. I would also like to highlight that we have recently appointed a new CEO to head our USA business. Based in the USA, he brings over 32 years of experience in medical devices and dental industry. His appointment will strengthen our on-ground leadership, enable a more market-focused strategy tailored towards the U.S. region, and support the continued scaling in one of our key international markets. Our aligner solution business also delivered another strong quarter, recording a healthy 28.6% year-on-year growth. With this segment, BizDent grew by 27.8% year-on-year, while Vidya registered a 29.3% year-on-year increase. These numbers reflect the effectiveness of our strategy for delivering sustainable and profitable growth. Such strong performance across all segments is attributed to our sustained efforts of our sales and ops team, supported by initiatives such as scanner deployment in the past, promotional activities, training programs, participation in dental events, and ongoing AI-related projects. Industry-wide, we see strong adoption of scanners in line with global trends. We continuously evaluate our scanner roadmap in line with technological advancements and innovations showcased at leading global dental exhibitions. Our pediatric dental business, Kizri Dental, continued its strong growth trajectory, delivering an impressive 54.4% year-on-year growth during this quarter, as the business is steadily scaling up. In FY27, we plan to make investments towards the addition of new machinery to modernize and expand the capacity of our manufacturing capabilities. These investments are aimed at supporting long-term growth while enhancing operational efficiencies across our business segments. We have also executed a letter of intent to acquire a new land situated in Palgur, Maharashtra. This is towards transitioning from our currently leased premises to a newly owned facility, which will enable us to improve the workflow efficiency and better control the cost structure. Further, it will also support the future scalability of our business. We will share further updates on this matter as and when there is progress. Going forward, we continue to execute our strategy centered around expanding our market reach, driving product innovation, accelerating digitalization, and building a trusted and a well-recognized brand in the dental industry. With this, we remain confident in delivering sustainable and long-term profitable growth. I will now hand it over to our CFO, Mr. Dharmesh Dattani, to take it forward. Thank you.

Thank you. Let me give a glance at our consolidated financial performance during Q1FI27. Revenue from operations stood at Rs. 74.7 crore as compared to Rs. 65.6 crore in Q1FI26, marking highest ever quarterly revenue for the company. Gross profit stood at Rs. 58.7 crore, registering a 22.1% YOY growth. Gross margin improved and stood at 78.6%. Employee cost stood at Rs. 28.4 crore with a sequential increase of 6.2%. This increase was primarily due to the appointment of a new CEO for the U.S.A. business and also due to some addition of employees across sales and other key important areas. Ease of expenses for the quarter stood at Rs. 83 lakhs. Other expenses increased to Rs.15.9 crore from Rs.12.5 crore in the same period last year, largely driven by higher trade costs, ECL provisions, and investment in AI-led automation initiatives, which are aimed at enabling greater efficiency and scalability going forward. EBITDA stood at Rs.14.4 crore, which is our highest ever quarterly EBITDA, registering a 20.6% YY growth. EBITDA margin stood at 19.2% in Q1 FY27. For better comparability, one can look at the adjusted EBITDA, which includes recorded EBITDA, 60% of KC Dental Pat, 49% of IDBG AI Dent Pat, and ESOP expenses. This stood at Rs. 16 crore as against Rs. 14.8 crore in the same period last year. Finance costs for the quarter stood at Rs. 0.3 crore as the company remains debt-free. Profit after tax for the quarter stood at Rs. 10.3 crore, registering at 23.8% worthwhile growth. Fed margins remained healthy at 13.8%. With this, we conclude our opening remarks and open the floor for Q&A. Thank you.

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Anyone who wishes to ask a question may press star and 1 on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and 2. Participants are requested to use their handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.

If you wish to ask a question, please press star and 1.

We take the first question from the line of Meet Mehta from Prasoon Expans. Chills, please go ahead.

Hello. Hi. Congratulations for the great set of numbers. Am I audible? Thank you so much.

Hello. Yeah, am I audible now? Yes, Prasoon, you are. Thank you.

So, my first question to you is, we don't have some exclusive tie-ups with the dentist. So, what makes the customer choose Lakshmi Dental product after using the iScan Pro Scanner? So, what differentiates it from the other products which the dentists have the option? That is my first question. Should I go with others or one by one?

Let's go one by one. I think it will be easier if you go one by one. Okay, no problem. So coming to your question of why, I mean, we've been doing this since 36 years, so trust is an important factor. So for any dentist choosing a dental prosthesis for a patient, first question is the trust partner. Do they trust the partner? And that we have built. Time and credibility factor. So which is when they want to send business to us, they know that we've been existing since 36 years, and they can trust the products. And there are dentists who have placed grounds 36 years back. So there's a history of that trust. Number two, in terms of quality standards. Now, you know, as an international company selling not just in India, worldwide, our quality standards are global. So when they choose a product, they know the material that we use, the processes that we use, the systems that we have in terms of ISO or quality management system. All are in place for them to get consistency when they are asking for any dental restoration. And then, you know, there are more parts of how we innovate, give them a better quality product in terms of our systems, processes, technology. So there are many factors, but I gave you one, two or three factors for them to choose us. And we have had history of they have chosen us. And even in the future, we have innovation, products, processes, branding as well, where we are the only branded players in the crown category. So these are a lot of parameters for them to make that decision.

Okay, understood. And my second question was on the scanner. So, what is the margin that you make on a gross level? And I think because of that, your margins can be a bit lumpy. So, how should we look forward about it?

So, even, I would say, on a scanner, usually, See, it's a trading item. So it will always have a normal trading margin of 15 to 20%, which usually any trading item would have. Now, if you see our margin, in fact, what we have been able to achieve at 19.2% as compared to last quarter, which was around 15, and even if YOY, it was at 18. So we have only improved our margins, and moving forward, we feel the mix will drive the margin in a good way, and excluding, if you exclude the scanner, so I would say if you want to look at stable margins, just exclude the scanner, and you will see the margins are stable and they are rising. With the scanner, it can happen that you will see minor fluctuations, but that is part and parcel of a business where we want to enable digital dentistry for long-term growth of the organization.

Okay, and what is the current capacity for lab business and the alliance? So, what is the utilization boost?

It's a little complex to measure because it's very custom made. You know, every crown is different. But although whatever best case scenario that we are measuring, the aligner has reasonable capacity to grow. I would say it is somewhere close to around 70% in terms of capacity, utilization. And the lab is probably slightly higher because it's more complex, more custom. Aligner still has a lot of automation involved. The lab has lesser automation than aligners, and that's why we are working towards automation and digitization. So on the lab part, I would say we are always on a constant threshold of like 90-95% because it's so custom. You know, it's very, very custom. Every prosthesis is designed differently, is manufactured in a custom manner. So it's a little complex, but I hope I gave you a perspective.

Right, right. And my last question is, what is currently the digital penetration among your network as of now?

So, we are currently, I would say, in the range of, it varies, you know, month on month, but I would say probably between 75 to 80% in domestic. Internationally, it's majority digital, but domestic, I would say we are in that range, combining our dental lab and align the business.

Okay, so as we reach towards more and more digital networks, so do you expect the scanner revenue going down?

See, again, scanner is a little complex here. So, we have done well in the scanner, and I would say moving forward also, we are keeping our eyes and ears open to see how the scanner business shapes up. But the industry is adopting scanners, for sure. I would say we are estimating it at around maybe 7% or maybe touching 8% right now. So there's a lot of headroom for the scanner to come in and digitization to happen. But we have to see when that, you know, J-Cov starts happening. So I would say for right now, there is a good demand, but we have to see how it moves further.

Okay. And what is the cost per scanner approximate?

Like I told you, so currently we are charging about 3 lakhs at an average for scanners to a dentist. Okay.

Okay. Okay. Understood. Yeah. Thank you. That's it from us. Thank you so much.

Thanks a lot.

Thank you. Participants, if you wish to ask a question, please press star and 1. We take the next question from the line of Anchit Ajalan from Goldman Sachs. Please go ahead. Yeah, you're a little slow, aren't you?

But, yeah.

Yeah, is this better? Is this better? Yeah, slightly better. Yeah, just a couple of things. One is, on this land parcel that we've acquired, what exactly is this for?

So, it is, so currently our domestic facilities are rented, both for the Illusion Dental Lab and for aligners, and they are two separate locations. So, the goal is to move away from rent and, you know, build a unified facility which can lead to operation efficiency and decreasing the rent. So, currently, we are almost paying close to two crores worth of rent just for these two properties. And now, you know, as, yeah, per year, as it's expanding, people are expecting a raise on the rental as well. So we thought, I think it's a good time for us to do something where we can have our own property. So it gives us room for expansion. You know, we can build almost 3x the size of what we are currently paying. So if we need to go 3x, you know, it'll end up at maybe 5-6 crores of just rent in the future. Instead of that, we can build it in a much more leaner manner.

Okay, and in terms of, let's say, disruption, then are you going to give up to the factories that are currently operating and then move to this one, or?

Oh, so that's the plan. Yeah, so the two facilities that are rented that we have, the plan is to let go of those and transition it to the newer facility, so that the rental goes up.

Okay, and what could be, like, the disruption in that transition period?

I don't see any disruption. See, the best part is because we are digital, it's much easier to make a moment today than to find that. If this was five years back, you know, probably more complicated. But because the technology is available right now, and we will do it in a very phased transition manner. It's not that we are going to create any disruptions in revenue or productivity while making this transition.

Even our explode business, also, you know, we initially was within the Mumbai, and we transitioned it to Boiser at a COVID period, which was 2020. And it was, I mean, a smooth transition for us.

Okay, all right. Couple of more questions. One is on the domestic labs business, what's happening? I mean, growth continues to be slightly slower. I mean, they're growing at about 12% exoscanners.

Yeah, this quarter YY is 12%. But if you see our messaging, we have added satellite labs, so we are much closer to the customer, and we only see the momentum upwards from here. I don't think we are going to be in that range. We will start growing faster in the domestic lab category in the coming quarters.

Okay. Okay. And just one last two things. Okay. So there was, one was on the employee expenses and on the other expenses. So on the new CEO that you've hired for the U.S. business, is it because you're seeing traction? Is this, you have a lead indicator and because of which you hired a U.S. CEO or is this a business that you're trying to expand and then for that purposes you've hired? And second is, can you... Please expand a little bit more on the AI-led automation expenses that you've outlined here.

Sure. So on the CEO part, definitely he has been or was in dental for the last 11 years, so he has that connect, and we have certain things which could really shape up extremely well in a couple of quarters with him. On the detailing part, maybe I'll prefer one-on-one when we can spend some time to give you of how and what are the things that the CEO brings to the table instead of, you know, on the call. And towards the other part of expenses on AI-led, well, so we are doing a lot of AI crowns already in beta, AI models. So there is some cost which is initial, which is coming in, which is slightly higher. But as we scale this up, you know, the cost will become much better. So probably a little bit for this year, but I think moving next year, the cost will be, I would say, much lesser than what it is right now. But at the same time, if you see, you know, we have been able to grow our margin from 18 to 19.2%. And we see that I think we are in a position to keep maintaining this or go higher as we move along throughout the year.

Great. Thanks a lot. Thank you. We take the next question from the line of Sushar Manudhane from Motilalo for Financial Services Limited. Please go ahead.

Thanks for the opportunity. So just on the international business side, if you could share how much has been the constant currency growth and how much has been the benefit of currency growth?

Tushar, hi. So, over the period of time, the USD has almost increased from 85 to 95. So, close to about 12% kind of the change in the USD over the YOY business. Simultaneously, our current business from the DSOs and the other existing retail business has also increased.

Sorry, sir, your voice cracked. So, what he's trying to say is there has been an uptick in, say, on a YOI side in terms of dollar, but even if it's approximately 10%, we have grown the business by almost 37%, the international.

No, no, sir. But, yeah, yeah, I mean, fair point. So, absolutely not taking away the constant currency growth. And just trying to understand that this benefit would continue for the coming quarters as well.

It will be there in place because we have to see how the USD has gone up from Q1 last year to Q1 this year, and then Q2, what was the price? Q2, what will be the price? We don't know. So we feel there may be some arbitrage, but we are still seeing very strong growth internationally.

Got it, sir. So, secondly, the aligner business has picked up really well with, you know, very decent growth shown for the quarter. What is it that is driving this and how sustainable that is?

We have done some good initiatives on Aligner with education, training, the iScope that we launched, which can do Aligner monitoring at home. That has given a lot of impetus to the business. We are also launching two, three more things as we speak in the next few quarters. We don't see any issue in sustaining the growth. We feel we should be able to keep the growth momentum going.

And while you elaborated on this point, but still sort of trying to understand that whatever scanners which we would have sort of sold to the dentist community earlier, typically how much time it would take to convert that to business and should reflect into better growth in domestic sales?

So I would say usually there is a gestation where we have seen between six months to a year in some scenario, maybe a year and a half as well. So what we have started seeing the trend of 12% growth, we feel that coming, I would say, towards the next three quarters, Q2, Q3, and Q4, we should only see it going upward in terms of growth trajectory as they mature more and more.

Thank you. Thank you, Vishal.

Thank you. Participants who wish to ask a question, please press star and one. We take the next question from the line of Priya Kulkarni from CM Capital. Please go ahead.

Hello, am I audible?

Yes, please go ahead.

Yes, thanks for this opportunity, sir. So I would like to ask that how do you expect to grow the domestic dental business at a faster rate going ahead? Like, what is the strategy on that front?

Hi, Priya. So there are multiple things. I think we've been constantly pushing the envelope with our scanners in terms of growth, and I think we are now hitting some maturity in terms of growing the domestic lab business, where we have seen in this Q1, 12%, and like I said in the previous question, which was asked, we only see that things should go upwards from here towards Q2, Q3, and Q4.

Okay, sir. I understood. Also, sir, would you like, like, I would also like to understand what is the competitive scenario on the NIMR business?

I think it's still there. It was there before. It is right now, and I don't expect it to go away from the future, but we as an organization will keep innovating. We'll keep making sure we utilize our experience of building the dental business in 36 years and cross-sell to a lot of our customers who are already giving us different aspects of our business. So, you know, I mean, it's there, like, to discuss on competition today, like we did it for a couple of times, but then you will devise counter-strategies to grow your own business, and that's what we have shown.

Right, right, sir. That answers my question. Thank you. All the best.

Thank you. Thank you. Participants, a reminder. If you wish to ask a question, please press star and one. We take the next question from the line of Hidvi Sanghvi from HS Investments. Please go ahead.

Hi, good morning. I just wanted to have an idea on this. Have you added any new international geography during the quarter?

Yeah, so we always, you know, constantly, the goal is to keep exploring newer countries across the world. So, yes, we have, and probably every quarter we have a few countries which get added on to the pilot phase, and then they go on to the next phase, and then eventually they start business.

Got it. And also, I just wanted to have an idea for aligners, who said a key target, target general dentist or orthodentist, and are we also looking at B2C opportunity here?

So, to come into your question, B2C, absolutely no. We are not selling aligners to patients directly, neither we intend to do so in the future as well. Our goal or our strategy is to go through the dentist, and in that, for us, you know, all dentists are same, whether it's orthodontist, general dentist, there is periodontist, there is endodontist. Basically, if they are dentists, we have orthodontist in-house. We have orthodontist on field who are our, you know, so-called advisors or part of team members where they support a dentist if they need help. So we go through only dentists, and we do not segregate much between an orthodontist and a general dentist. Because if you see internationally, even globally as well, there is a lot of revenue now coming in from general dentists worldwide, not just in India, but across the world. As the aligners are becoming more, I would say, option for patients, it is getting simpler because a lot of companies like us are driving education towards the dentist. Tenters and the dentists are experiencing how they do aligners and getting more and more confident about delivering it.

Got it, got it. Yeah, that answers my question. Thank you so much for the opportunity.

Thank you, Hathree. Thank you. Participants who wish to ask a question, please press star and one. We take the next question from the line of Anshith Jalan from Goldman Sachs. Please go ahead.

Hi, thank you for taking my question again. So I just want to understand, on scanners, what is the strategy going forward in terms of how much are we planning to deploy for the current year?

So, current year, based on, you know, last estimate, we had thought that we should be able to again deploy about 800 to 1,000 in this financial year. And like I said before, you know, we are looking at the technology, looking at the scanner's demand, the scanner adoption, you know, every day as we speak. So, we are still, we still feel that we should be on track to do that in this year.

Okay. So, in terms of gross margins, then, should we expect gross margins to be similar to what we had in 1Q?

Yeah, yeah, I think absolutely. So, again, now, when you say gross margin, when the scanner makes changes, there is always a slight change. Apart from scanner, the margin should remain stable. But if we have, like, a very strong quarter in terms of scanner, we will see there is a dip in the gross margin because the scanner is sold at, say, 20% margin. So 80% is our cost. So then that adds the future like we are seeing with the aligners right now, and Dental has started again two-digit momentum in terms of growth. So it will keep continuing that momentum for future years as well.

Give some, you know, direction in terms of guidance, in terms of, let's say, EBITDA or revenue.

So, I think in last time, yeah, so on the aspiration side, so we had said that on the revenue side, 15% to 20% growth, and on the margin side, you know, 18% to 20% is the goal. And we have done that in the past. Now, last year, there were a lot of situations because of which we were at about 15.6%. The labor code came into picture, a lot of tariffs came into picture, then a big amount of ESOP cost came into picture, but now ESOP is now pretty normal, you know, it's almost half of what it was last year. So, we feel we should be in that range.

Okay, okay. Okay, that's it. Thank you so much.

Perfect. Thank you. Thank you. For a special reminder, if you wish to ask a question, please press star and 1. We take the next question from the line of Grishikesh, Raj Singh, an individual investor. Please go ahead. Grishikesh, your audio is not clear. Could you please use your handset? Is it better now? Yeah, much better. Thank you.

Okay, so my question is on the price. I actually bought Lakshmi Natal Chase in Jan 2025 at around 500 rupees. Currently, it's at 200 rupees. So yesterday, I was very eagerly waiting for the results. When I saw the results, my personal opinion was this was a great result. I was looking forward to a great upside moment this morning, but disappointingly, it has gone down. So what is it that we are missing here? What is it the market is trying to tell us?

Now again, Rishikesh, I wish I had an answer which I could give you, but this is not in our hands. What is in our hands today is to perform. Like you said, it's a great result. We believe that we did very well for Q1. Correct. Our margins improved. Our revenue is, you know, this is the best quarter that we have ever had. In terms of profitability, we are at 19.2%. So the controllables are with us in terms of performance. And what we are doing since last 36 years as, you know, management, we will keep working hard, keep doing good for the business. Apart from that, very hard for us to control anything which is what is happening externally. In fact, if you see, we had, and this is public news, we had actually purchased shares when the pricing was, you know, somewhere in the range of, I think, 200. We actually bought shares. So we still believe, and whenever time comes in the future, when we have liquidity, we will keep buying. So we are very bullish, positive about what we have created. And if you see the dental awareness in India or anywhere in the world, it's not going down. The awareness is only going up. So for us, the next five, ten years are, you know, we are so excited about what next five or ten years brings to dentistry for us, not just in India, but across the world. And that is why, you know, we are trying to control our control level, which is to perform. Like you saw the numbers, you know, we have had congratulation messages, so it's even hard for us to understand why this is happening. But all we can do, and I can assure you that we will keep trying our best and we'll keep performing.

Okay, thank you.

Thank you, sir. Thank you. Partisans, if you wish to ask a question, please press star and one. We take the next question from the line of Devanshi Shah from HUF Capital. Please go ahead.

Hi, thank you for the opportunity. Sir, I wanted to understand, sir, what initiatives are you taking for building a brand in the dental industry?

Hi, Devanshi. Thanks so much. I'm so happy to hear that question about branding in dentistry. So what we have done is we have got brand ambassadors on board. We are doing a lot of in-clinic branding. We are advertising on social media and a lot of other channels where we are trying to educate a patient to ask your dentist about the right kind of restoration. So those are a lot of initiatives that we are doing. I think branding is important because today, you know, when I meet a lot of people, I say, what is it that we pick without a brand? Anything on our body, inside our body, when we have to pick something, we are picking up with a brand. Whether it's as small as a bottle of water, which is costing us 10 rupees, or anything which is very, very expensive, we are always looking for a brand. So, dentistry, I think, deserves a brand. You know, we have started first, so that's why it's tougher, but we like doing, you know, tougher things. And we are very, very positive that branding is a long-term play, and eventually in the next 3, 4, 5, 7, 10 years, branding will become one of the biggest differentiators of a patient and a dentist who are choosing a dental product.

Definitely, sir. Got it, sir. Thank you.

Thank you so much. Thank you. We take the next question from the line of Parchus from Logstar Equity Research. Please go ahead.

Hello, sir. I want to understand, I mean, if we see now that business is growing at almost 30% CAGR, I mean the entire industry, and if I see your breakdown, you have also mentioned that you have grown 29% here on here from 185 to 238 million. So, I want to understand in the future, you just planning to grow the industry CAGR or you want to outgrow it exponentially in the long term?

Thank you for your question. I think always, you know, as market leaders, the goal that we have is to grow beyond the industry. So it is not that we want to grow with the industry, and we are putting in a lot of efforts in terms of how we can grow, whether it's the branding that we did with Kaleena Kapoor as a brand ambassador, whether it's the aligner education, or whether it's training to the dentist, or whether it's social media marketing towards the patient. So the efforts and initiatives are there. And I'm sure in the future, we will see good results. In the next three to five years, we should be able to bring a very, very strong line of brand in the country.

And what about the ratio, sir? Like, I have seen currently the majority of the revenue is coming from the laborator offerings. So, in the long term, where do you want to focus more, sir? Do you want to scale other solutions or do you want to focus more on laborator offerings?

I think it's important for us to see Lakshmi Dental as a holistic company and not break it down too much because in the end, we are working with dentists who are our customers. So if the dentist has today more dental lab business and lesser aligner business, maybe the mix would be similar. In the future, if aligners, you know, really explode, which it has done in many countries, if a dentist are doing more aligner cases, then probably that mix will change. But for us, we look at it from a holistic viewpoint where dentist is our person where we get revenue from, whether it's the revenue for dental lab, whether it's the revenue for aligner or any other product. That is how we look at it.

Okay, thank you.

Thank you.

Thank you. Ladies and gentlemen, as there are no further questions from the participants, I now hand the conference over to the management for their closing comments.

Thank you so much. With this, we conclude the call. If you have any further queries, please contact SGA, our investor relationships advisor. Thank you, everyone, for joining us today on this learning call. Thank you. Thank you.

On behalf of Lakshmi Dental Limited, that concludes this conference call. Thank you for joining us, and you may now disconnect your line.